Forte Biosciences
Anti-CD122 monoclonal antibody therapeutic
- Sector
- Biotech
- Headquarters
- DALLAS, TX
- Founded
- 2007
- Latest Form D
- $25M, Aug 2023
- Total capital
- $44.1M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $44.1M
- 9 Form D · last Aug 2023
- 38 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- None on recordNo USPTO grants. Applications publish after 18 months.
Capital Timeline
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $25,009,981 | |
| Private capital raised | Form D · SEC | $2,735,750 | |
| Private capital raised | Form D · SEC | $210,000 | |
| Private capital raised | Form D · SEC | $1,150,000 | |
| Private capital raised | Form D · SEC | $1,058,002 | |
| Private capital raised | Form D · SEC | $2,135,000 | |
| Private capital raised | Form D · SEC | $7,776,750 | |
| Private capital raised | Form D · SEC | $3,000,001 | |
| Private capital raised | Form D · SEC | $1,000,000 |
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3389 | PhaseBio Pharmaceuticals Inc | — | $63.7M |
| 3390 | OPUS GENETICS INC. | — | $46.9M |
| 3391 | CERo Therapeutics, Inc. | — | $44.6M |
| 3392 | Forte Biosciences | — | $44.1M |
| 3393 | Oncotelic Therapeutics, Inc. | — | $40.3M |
| 3394 | ADVANTAGENE, INC | — | $35.9M |
| 3395 | Allarity Therapeutics, Inc. | — | $26.9M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Franklin BergerDirector
- Dennis BermanDirector · Executive Officer
- Scott BrunDirector
- Hubert ChenExecutive Officer
- Thomas DarcyDirector · Executive Officer
- Stephen DobersteinDirector
- Martin DuvallDirector · Executive Officer
- Lawrence EichenfieldDirector
Show all 21 people
- Barbara FinkDirector
- Mark FolettaExecutive Officer
- Harry GruberDirector · Executive Officer
- David GryskaDirector
- Faheem HasnainDirector
- Douglas JollyExecutive Officer
- Steven KornfeldDirector
- Lori KunkelDirector
- David ParkinsonDirector
- Antony RileyExecutive Officer
- Paul SchimmelDirector
- Paul WagnerDirector · Executive Officer
- Donald WilliamsDirector
Patents
No patents are on record under this company's name.
USPTO publishes applications about 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won't match.
Checked: USPTO granted patents and published applications
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.